Announcement on 2025 Annual Profit Distribution Plan
Filed with SSE · · 1 page · Chinese
Vcanbio Cell & Gene Engineering Corp., Ltd. on 6ix
Earlier from Vcanbio Cell & Gene Engineering
- Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection
- Announcement on Progress in Using Temporarily Idle Raised Funds for Cash Management
- Announcement on Redemption of Idle Raised Funds Used for Cash Management upon Maturity
- Announcement on Subsidiary’s Receipt of a Medical Device Registration Certificate
- with the University of Chinese Academy of Sciences Education Foundation and the Progress in Hosting the Vcanbio Life Sciences Award
Later from Vcanbio Cell & Gene Engineering
- Indicative Announcement on Convening the 2025 Annual General Meeting
- Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Convening the 2025 Annual Performance Briefing
- Announcement on Progress in Redemption of Temporarily Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
Follow Vcanbio Cell & Gene Engineering into a list and get an email when it puts out news.
Follow Vcanbio Cell & Gene Engineering